MabCure, Inc. (MBCI)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0090 - Volume
2,580 - Avg. Volume
40 - Market Cap (intraday)
514,912 - Beta (5Y Monthly) 13.66
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.
Related News
Performance Overview: MBCI
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MBCI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MBCI
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
1.29
Enterprise Value/EBITDA
-0.05
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-4.22%
Return on Equity (ttm)
-125.14%
Revenue (ttm)
500k
Net Income Avi to Common (ttm)
-12.26M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
146.44k
Total Debt/Equity (mrq)
7.87%
Levered Free Cash Flow (ttm)
114.53k
Company Insights: MBCI
MBCI does not have Company Insights